Reviewed by Roey Hine
Key Takeaways
- Urology denials cluster around specific procedures, not one universal coding mistake.
- CPT 55700 was deleted for 2026 and replaced by a nine-code family that bundles imaging into the biopsy code itself.
- NCCI edits bundle diagnostic cystoscopy into nearly every therapeutic cystoscopy code performed in the same session.
- Missing laterality modifiers on lithotripsy and kidney stone claims cause automatic rejections.
- TURBT code selection depends on tumor size documented in the operative note, not the technique used to remove it.
Urology denials rarely trace back to one universal mistake. Cystoscopy, prostate biopsy, lithotripsy, and bladder tumor resection each carry separate coding rules, separate National Correct Coding Initiative (NCCI) edits, and separate documentation requirements. A practice that cleans up its modifier habits but is still billing prostate biopsies the way it did in 2025 is still losing revenue on every one of those claims. Here is where denials actually happen, procedure by procedure, and what optimizing each one requires.
Cystoscopy and Bladder Procedures: When Diagnostic Codes Get Bundled Away
Diagnostic cystoscopy, CPT 52000, carries a “separate procedure” designation in the CPT code book. Under the CMS National Correct Coding Initiative, that designation makes 52000 a Column Two code against nearly every therapeutic cystoscopy service in the 52001 through 52356 range, including cystoscopy with biopsy (52204), fulguration or resection of bladder tumors (52234), and ureteral stent placement (52332). When a urologist performs a diagnostic look and treats what they find in the same session, only the therapeutic code gets paid. Billing 52000 alongside it triggers an automatic denial before a reviewer ever sees the claim.
The exception is a genuinely separate service: a diagnostic cystoscopy performed at a different anatomical site or during a distinct session from the therapeutic procedure. That distinction needs to be explicit in the operative note, along with modifier 59 to signal it to the payer. Without that documentation, the more accurate approach is to code only the comprehensive procedure and let the diagnostic component fold into it.
The 2026 Prostate Biopsy Code Overhaul Is Still Catching Practices Out
The AMA deleted CPT 55700, the code that had covered nearly every type of prostate biopsy, effective January 1, 2026. Eight months in, claims still get denied when a practice reports 55700 out of habit or keeps billing imaging guidance on a separate line the way it always used to. The replacement is a nine-code family organized around two questions: which approach did the urologist use, and which imaging guided it.
The replacement codes break down by approach and guidance method:
- 55705, revised for 2026, for non-imaging-guided biopsy
- 55706, unchanged, for transperineal stereotactic template-guided saturation biopsy, a distinct high-core-count procedure usually done under anesthesia
- 55707 through 55712, new codes covering transrectal and transperineal biopsies guided by ultrasound alone or ultrasound with MRI fusion
- 55713 and 55714, for in-bore CT- or MRI-guided biopsy of additional or targeted lesions
- 55715, an add-on code for each additional targeted lesion under fusion or in-bore technique
A common source of overpayment risk before 2026 was billing 55706 for a standard transperineal ultrasound-guided biopsy rather than the saturation procedure it actually describes; the new code family closes that substitution, but only for practices that have updated their superbills and EHR templates to match. Imaging guidance codes like 76872 and 76942, previously billed alongside 55700, are now bundled into every code in the 55705 through 55715 family and can no longer be reported separately. Targeted lesions are also billed once per lesion, not by the number of core samples taken. Operative notes need to state approach and guidance method precisely enough for a coder to select the right code on the first pass.
Kidney Stone Management and Lithotripsy: Why Laterality Decides the Claim
Extracorporeal shock wave lithotripsy, CPT 50590, is billed once per kidney per session regardless of how many stones the urologist fragments or how many shock waves it takes. The code is comprehensive: It includes stone localization, fluoroscopic guidance, and routine post-procedure imaging. Billing those components on separate lines triggers an NCCI denial.
Where lithotripsy claims actually fail is laterality. CMS requires RT or LT modifiers on procedure codes describing services to an anatomic structure that can be right- or left-sided, and claims submitted without them are rejected outright as unclear or duplicate services. For bilateral stone treatment performed in the same session, modifier 50 applies instead. A staged repeat treatment within the 90-day global period needs modifier 58 to show it was planned in advance rather than a failed first attempt; an unplanned return for a complication uses modifier 78. Confirming laterality and staging modifiers before submission catches most of these denials before they happen.
TURBT and Bladder Tumor Resection: The Size Threshold That Sets the Code
TURBT codes are built around a single variable: tumor size, measured intraoperatively and recorded in the operative note. CPT 52234 covers small bladder tumors from 0.5 to 2.0 centimeters, 52235 covers medium tumors from 2.0 to 5.0 centimeters, and 52240 covers large or multiple tumors. When the operative note doesn’t state a measurement, payers default to the lowest-paying code in the family or deny the claim for insufficient documentation, regardless of what was actually removed.
The diagnostic cystoscopy used to locate the tumor is included in every code in the 52234 through 52240 range, the same bundling rule that governs 52000 elsewhere in cystoscopy billing. When multiple tumors are resected in one session, code selection follows the largest tumor treated; smaller tumors resected at the same time are included, not billed separately. Fixing this means changing a documentation habit: Every operative note needs a specific measurement rather than a general description of the tumor.
Modifiers 25, 59, and 51: When Each One Actually Applies
Modifier 25 applies when a urologist performs a significant, separately identifiable evaluation and management service on the same day as a procedure, such as a new BPH workup during the same visit as a scheduled cystoscopy. The E/M documentation has to stand on its own as a distinct service, not simply restate the reason for the procedure already being performed.
Modifier 59 and its more specific X-modifiers apply to two procedures that would normally bundle together but were performed at different sites, during different sessions, or on distinct anatomic structures. In urology, this shows up most often with mitomycin instillation billed as a distinct service after TURBT, or a genuinely separate diagnostic cystoscopy apart from a therapeutic one. The X-modifiers break 59 into more specific flags:
- XE: a separate encounter
- XS: a separate organ or structure
- XP: a separate practitioner
- XU: an unusual, non-overlapping service
Payers increasingly prefer the more specific X-modifier when documentation supports it, since it leaves less room for a reviewer to question why 59 was applied. Modifier 51 signals multiple procedures performed in the same session, and most payers apply it automatically through claims processing software rather than requiring practices to append it manually. Appending it where a payer doesn’t expect it, or omitting it where manual entry is still required, is a smaller but recurring source of underpayment.
Optimizing Urology Claims Before They’re Submitted
Every rule above shares the same fix: catching the error before the claim goes out, not appealing it after a denial arrives. Practices leaning toward outsourcing often proceed with doing so for exactly these reasons, including recurring cystoscopy and TRUS biopsy denials, modifier misapplication, and inconsistent prior authorization tracking. That’s what our overview of outsourced urology billing and RCM covers in more detail.
For practices ready to act on it, PGM’s urology billing services team works inside these coding rules every day. Contact us to learn what our urology revenue cycle management experts can do for you.
* * *
Frequently Asked Questions About Urology Billing
What ICD-10 codes commonly support urology procedure claims?
Common pairings include N20.0 and N20.1 for kidney and ureteral stones, N40.0 and N40.1 for BPH with and without lower urinary tract symptoms, N52.9 for erectile dysfunction, R33.9 for urinary retention, and C61 for prostate cancer. Diagnosis codes need to match the specificity documented in the operative note, particularly laterality for stone and kidney procedures. PGM’s urology ICD-10 code reference covers the fuller list of commonly reported codes and their typical billing context.
Does Medicare limit how often ESWL can be billed for the same kidney stone?
Yes. CPT 50590 is billed once per kidney per treatment session regardless of the number of stones fragmented. A planned, staged repeat treatment within the 90-day global period requires modifier 58; an unplanned return for a complication uses modifier 78. A new stone treated well beyond the global period is billed as a fresh 50590 with no modifier.
Is prior authorization required for lithotripsy or prostate biopsy?
Most commercial payers require prior authorization for ESWL, PCNL, and image-guided prostate biopsy procedures, though requirements vary by plan. Confirming authorization before scheduling, rather than after the procedure, prevents denials that documentation alone can’t fix.
What’s the difference between modifier 59 and modifier XS in urology billing?
Modifier 59 is the general-purpose flag for a distinct procedural service that would otherwise bundle with another code on the same claim. XS is a more specific subset of 59, used when the distinct service involves a separate organ or structure. Payers increasingly favor the more specific X-modifier when documentation supports it.
Can a urologist bill an E/M visit and a procedure on the same day?
Yes, with modifier 25 on the E/M code, but only when the visit involves a significant, separately identifiable service beyond the standard pre-procedure evaluation. A same-day BPH medication review during a scheduled cystoscopy visit typically qualifies. A brief check-in confirming the patient is ready for the already-scheduled procedure generally does not.